Abstract 537P
Background
Pulmonary metastasectomy is a commonly performed operation, but with inconclusive evidence for effectiveness. The aim of this study is to investigate the patient outcome after pulmonary metastasectomy in sarcoma patients with pulmonary metastases.
Methods
We retrospectively reviewed patients undergoing pulmonary metastasectomy for metastatic soft tissue and bone sarcomas in a single center. Treatment-free interval (TFI) was defined as the duration from the last date of primary tumor treatment to pulmonary metastasectomy. Recurrence-free interval (RFI), defined as the time from pulmonary metastasectomy to identification of new pulmonary metastasis, was calculated to determine freedom from lung recurrence. Post-metastasectomy survival (PMS) was defined as the time from pulmonary metastasectomy to death. Kaplan-Meier plots and Log-rank test were used to identify prognostic factors.
Results
Data of 102 patients were include in the analysis. In the RFI analysis, 77.4% patients (79/102) developed new pulmonary metastasis after pulmonary metastasectomy, with a median duration of 8.9 months. The 2-year freedom from lung recurrence was 23.6% and 51.9% in patients with TFI less than 12 months and TFI more than 12 months, respectively (p = 0.040). In the PMS analysis, the extrathoracic recurrence (p = 0.004) and TFI, but not primary site tumor recurrence, were significant prognostic factors. The 2 and 5-year PMS rates were 68.5% and 38.1%, respectively, in patients in patients with TFI less than 12 months, compared to 80.3% and 67.6%, respectively, in patients with TFI more than 12 months (p = 0.028).
Conclusions
A significant proportion (77.4%) of patients developed lung recurrences after pulmonary metastasectomy for sarcoma. Patients with TFI more than 12 months were associated with higher rate of freedom from lung recurrence and better PMS after pulmonary metastasectomy for sarcoma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
123P - Spatial molecular profiling identifies FGF20 upregulation on cancer-associated fibroblast and FGFR2-PI3K/Akt activation in tumor cells of sporadic early-onset colon cancer
Presenter: Dave Hoon
Session: Poster Display
Resources:
Abstract
124P - Characteristics, prognosis and therapeutic effects of non-V600 BRAF mutated colorectal cancer
Presenter: Lalida Arsa
Session: Poster Display
Resources:
Abstract
125P - Final results of APOLLON-11 and SOYUZ-APOLLON study: Multicentre prospective observational post-authorization study of bevacizumab biosimilar in patients with metastatic colorectal cancer in real-world practice
Presenter: Alexey Tryakin
Session: Poster Display
Resources:
Abstract
126P - From tumor height (TH) to tumor regression grade (TRG) in locally advanced rectal cancers (LARC) during total neadjuvant therapy (TNT): A retrospective analysis
Presenter: Valeria Pusceddu
Session: Poster Display
Resources:
Abstract
127P - A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness
Presenter: Takayuki Yoshino
Session: Poster Display
Resources:
Abstract
128TiP - A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
140P - Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
Presenter: Hoo Hwoei Fen Soo
Session: Poster Display
Resources:
Abstract
141P - Early phase trials outcomes in refractory upper GI cancers: A 10-year analysis from the SCRI UK phase I unit
Presenter: Antonella Cammarota
Session: Poster Display
Resources:
Abstract
142P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract